4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Sees Large Growth in Short Interest

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totaling 8,677,770 shares, a growth of 72.7% from the December 15th total of 5,023,933 shares. Currently, 16.8% of the company’s stock are sold short. Based on an average trading volume of 1,473,096 shares, the short-interest ratio is presently 5.9 days. Based on an average trading volume of 1,473,096 shares, the short-interest ratio is presently 5.9 days. Currently, 16.8% of the company’s stock are sold short.

4D Molecular Therapeutics Stock Down 0.8%

Shares of FDMT traded down $0.06 during mid-day trading on Friday, hitting $7.55. 754,442 shares of the company’s stock were exchanged, compared to its average volume of 942,831. The firm has a market cap of $431.33 million, a price-to-earnings ratio of -2.01 and a beta of 2.99. The stock’s 50-day simple moving average is $9.45 and its 200-day simple moving average is $8.00. 4D Molecular Therapeutics has a 52 week low of $2.23 and a 52 week high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.01) EPS for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.01. The firm had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.40 million. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%. Analysts forecast that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on FDMT. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, October 8th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, January 7th. Leerink Partners reiterated an “outperform” rating and issued a $17.00 price objective on shares of 4D Molecular Therapeutics in a report on Friday, October 31st. Barclays cut their target price on shares of 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating for the company in a research note on Tuesday, November 11th. Finally, Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.25.

Insider Buying and Selling

In related news, insider Scott Bizily sold 2,678 shares of the stock in a transaction on Friday, October 24th. The shares were sold at an average price of $12.00, for a total transaction of $32,136.00. Following the completion of the transaction, the insider owned 3,594 shares in the company, valued at approximately $43,128. This represents a 42.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders sold 6,337 shares of company stock valued at $70,649. Insiders own 9.60% of the company’s stock.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Large investors have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd acquired a new position in shares of 4D Molecular Therapeutics in the 1st quarter valued at approximately $39,000. Wexford Capital LP acquired a new position in 4D Molecular Therapeutics during the third quarter valued at approximately $41,000. Los Angeles Capital Management LLC bought a new stake in 4D Molecular Therapeutics during the second quarter worth $42,000. Quadrature Capital Ltd acquired a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at $42,000. Finally, Farther Finance Advisors LLC increased its stake in shares of 4D Molecular Therapeutics by 117.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after purchasing an additional 2,674 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.